Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

Recruiting

Phase 1

Phase 2

Enfortumab Vedotin & Stereotactic RadiationEnfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

Sponsor:

University of Texas Southwestern Medical Center

Code:

NCT06394570

Conditions

Bladder Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Enfortumab vedotin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-03. This information was provided to ClinicalTrials.gov by University of Texas Southwestern Medical Center on 2024-09-19.